Conference Day 2 Day One Wednesday, December 8 Day Two Thursday, December 9 8:30 am Coffee & Networking 9:15 am Chair’s Opening Remarks Yvonne McGrath Vice President R&D, iTeos Therapeutics Characterizing Anti-TIGIT Drug Candidates to Inform Validation & Transition into Clinical Investigations 9:30 am LIGHTing the Way for TIGIT Blockade in CPI Refractory Tumors Taylor Schreiber CEO, Shattuck Labs 10:00 am Revealing New Data on the Regulatory Role of TIGIT in Acute Myeloid Leukaemia Walter Fiedler Associate Professor, University Medical Center Hamburg-Eppendorf Franziska Brauneck Assistant Doctor, University Medical Center Hamburg-Eppendorf 10:30 am Morning Refreshments & Networking Enhancing TIGIT Therapies through Targeting Checkpoint Inhibitors in the DNAM-1/CD226 Axis 11:00 am Exploring the CD226 (DNAM-1) Axis to Improve on TIGIT’s Clinical Benefit Jeremy Waight Scientific Director, GlaxoSmithKline 11:30 am Restoring DNAM-1/CD226 Surface Expression with a Potent Anti-PVR mAb, NTX-1088, to Induce Anti-Tumor Immunity Pini Tsukerman Chief Scientific Officer, Nectin Therapeutics Ltd. 12:00 pm Harnessing PVRIG & TIGIT Combination in Anti-Cancer Immunity Eran Ophir Vice President Research & Drug Discovery, Compugen Ltd. 12:30 pm Lunch & Networking Utilizing Biomarkers to Maximize Clinical Effect 1:20 pm Chair’s Opening Remarks Farahnaz Forozan President, Forozan OncoGen Consulting 1:30 pm Personalizing TIGIT Therapy Strategy through Patient Stratification to Enhance Clinical Response Sandhya Girish Vice President Clinical Pharmacology, Gilead Sciences Glimpsing at Future Directions in Cancer Indications 2:00 pm Investigating the TIGIT Blockade in Melanoma: Where are We Now, Where to Go Next Diwakar Davar Assistant Professor of Medicine, Melanoma & Phase I Therapeutics, University of Pittsburgh Medical Center, Hillman Cancer Center 2:30 pm Outlining the Clinical Expansion of TIGIT Therapies Beyond NSCLC Kartik Krishnan Vice President, Clinical Development, Arcus Biosciences 3:00 pm Closing Remarks & Close of Summit